Invitrogen, PamGene to Co-Market Nuclear Hormone Receptor Products | GenomeWeb
NEW YORK (GenomeWeb News) – PamGene International announced today that it has entered into a co-marketing pact with Invitrogen covering nuclear hormone receptor products.
Under the alliance, the firms will co-market Invitrogen’s nuclear hormone receptor proteins and Lanthascreen assay technology with PamGene’s microarray-based nuclear hormone receptor screening tools including its PamChip applications and PamStation instruments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.